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Abstract: The early diagnosis of oral squamous cell carcinoma (OSCC) is still an investigative 
challenge. Saliva has been proposed as an ideal diagnostic medium for biomarker detection by mean 
of liquid biopsy technique. The aim of this pilot study was to apply proteomic and bioinformatic 
strategies to determine the potential use of saliva small extracellular vesicles (S/SEVs) as a potential 
tumor biomarker source. Among the twenty-three enrolled patients, 5 were free from diseases 
(OSCC_FREE), 6 were with OSCC without lymph node metastasis (OSCC_NLNM), and 12 were 
with OSCC and lymph node metastasis (OSCC_LNM). The S/SEVs from patients of each group 
were pooled and properly characterized before performing their quantitative proteome comparison 
based on the SWATH_MS (Sequential Window Acquisition of all Theoretical Mass Spectra) method. 
The analysis resulted in quantitative information for 365 proteins differentially characterizing the 
S/SEVs of analyzed clinical conditions. Bioinformatic analysis of the proteomic data highlighted that 
each S/SEV group was associated with a specific cluster of enriched functional network terms. Our 
results highlighted that protein cargo of salivary small extracellular vesicles defines a functional 
signature, thus having potential value as novel predict biomarkers for OSCC. 




Oral squamous cell carcinoma (OSCC) is one of the most prevalent histotypes of 
cancer worldwide and is a challenge to public health. Despite the introduction of new 
diagnostic tools and treatment modalities for the management of OSCC, its prognosis still 
remains very poor, with a 5-year mortality rate of approximately 60% [1]. Although the 
accessibility of the oral cavity can render the clinical examination easy, OSCC is usually 
diagnosed in advanced stages due to diagnostic delay, which obviously decreases the 
chances of survival [2,3]. 
To date in current clinical practice, OSCC diagnosis is usually preceded by oral visual 
examination, including inspection and palpation, by general physicians or dentists. In 
cases of suspicious neoplastic lesions, the clinical examination is integrated by incisional 
biopsy followed by histological investigation; however, no specific and reliable molecular 
markers are yet available [2,4,5]. Thus, more recent research has been focusing on the 
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identification of non-invasive or minimally invasive markers for OSCC screening and 
longitudinal monitoring of the patients’ response to treatment. In this context, liquid 
biopsy is a promising method for early diagnosis and real-time monitoring based on the 
analysis of circulating tumor cells (CTCs), circulating tumor DNAs (ctDNAs), circulating 
cell-free microRNAs (cfmiRNAs), extracellular vesicles (EVs), and other cancer-derived 
products isolated by the blood or other biofluids (e.g., saliva, urine, ascites, pleural 
effusion, etc.) [5–8]. Liquid biopsy allows one to obtain a real-time picture at different time 
points, giving information about tumor and tumor burden as well as early evidence of 
drug resistance and tumor recurrence [4,9], supporting the development of more highly 
personalized diagnosis and therapies [7,10]. In recent years, several studies have been 
focused on describing the use of EV-based liquid biopsy as a source of biomarkers for 
several kinds of cancer [11–14]. 
EVs are heterogeneous membranous structures secreted by all living cells, including 
cancer cells, in the surrounding microenvironment, as well as in proximal and systemic 
body fluids. 
Historically, EVs, based on their biogenesis, were classified in exosomes (of endocytic 
origin) and microvesicles (directly shed by the plasmatic membrane); however, since it is 
not always easy to establish the presence of specific markers of subcellular origin, the 
International Society for Extracellular Vesicles (ISEV) suggests indicating EV subtypes 
with reference to physical characteristics of EVs, such as the size. Thus, now it is more 
appropriate to refer to “small EVs” (SEVs, < 200 nm) and “medium/large EVs” (M/LEVs) 
[15]. 
From a functional point of view, SEVs are described as cell-free messengers playing 
a crucial role in cell–cell communication, strongly depending on the nature of the 
transported active biomolecules (proteins, mRNAs, miRNAs, and lipids). A significant 
body of literature has demonstrated that the SEVs released by tumor cells have an active 
role in promoting tumor growth and progression [16–18] and carry tumor-specific RNAs 
and proteins that are considered attractive targets for diagnostic application [19–21]. 
Moreover, for their high stability in the circulation and body fluids, SEVs are considered 
one of the more promising elements characterizing the liquid biopsy. Among the 
biological fluids, saliva is proposed as an ideal diagnostic medium for biomarker 
detection. The main advantages of using saliva are its non-invasiveness, ease of collection, 
and cost-effectiveness, as well as the possibility of detecting low-abundance biomarkers 
often untraceable in blood or serum samples, which have a more complex molecular 
composition. In the last 15 years, several studies have widely demonstrated that saliva 
mirrors the conditions of the oral cavity (as its proximal fluid) but also of the whole body, 
thus supporting the application of salivary diagnostics for systemic and oral diseases [22–
24]. Among the components of saliva, SEVs are considered as a specific and stable source 
of biomarkers, since by reducing the complexity of the whole saliva, they can provide 
more accurate and clinically relevant information for disease detection and diagnoses [25]. 
In the last decades, proteomics technologies have represented promising tools for 
disease-associated biomarker detection, offering the possibility of analyzing the global 
protein profile of a sample (tumor tissues, body fluids, vesicles). The comparative analysis 
of protein profiles identified in “normal” and “disease” samples and the following 
bioinformatic analysis allow one to define a panel of aberrantly expressed proteins that 
can increase the accuracy of current diagnostic methods. 
In this study, we applied proteomic and bioinformatic strategies to determine the 
potential use of saliva small extracellular vesicles (S/SEVs) derived from OSCC as a 
potential tumor biomarker source. The proteome profiles of S/SEVs from subjects without 
OSCC (OSCC_FREE) and from OSCC patients without and with lymph node metastasis 
(OSCC_NLNM and OSCC_LNM, respectively) were compared using the quantitative 
proteomic SWATH-MS (Sequential Window Acquisition of all Theoretical Mass Spectra) 
method. For the first time, this study reveals that the S/SEVs have a specific protein 
signature differentiating not only healthy controls from OSCC patients but also NLNM 
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patients from LNM ones, showing their potential use as non-invasive liquid biopsies for 
improving the diagnostic routines and the clinical outcomes of OSCC patients. 
2. Results 
2.1. Enrolled Subjects and Sample Collections 
Among the 23 subjects enrolled in this study, 5 were without OSCC (OSCC_FREE 
group) and 18 were patients with OSCC, of which 6 were without lymph node metastases 
(NLMN) and 12 with lymph node metastases (LMN) (Figure 1A). Demographic and 
clinical/anamnestic data of each group are summarized in Table 1. For all groups, the 
mean age was over 60 years; the OSCC_FREE group was closer to being gender-balanced 
(# males = 3, 60%; # females = 2, 40%), while a female prevalence was observed in the 
OSCC_NLNM group (# females = 5, 83.3%) and a male prevalence was observed in the 
OSCC_LNM group (# males = 8; 66.7%). In the OSCC_FREE group, only one subject was 
a current or former smoker (20%), while the smokers numbered two (33.3%) and seven 
(58.3%), respectively, in the OSCC_NLNM and OSCC_NLNM groups. Finally, most of the 
enrolled subjects were non-drinkers: 100% (5/5) in the OSCC_ FREE group and 83.3% in 
the OSCC_NLNM and OSCC_LNM groups (respectively, 5/6 and 10/12). 
 
Figure 1. (A) Saliva samples used in the study. (B) Flowchart of S/SEV purification protocol. 
Table 1. Demographic and clinical/anamnestic data of the enrolled patients. 
Anamnestic Data OSCC_FREE Group (n = 5) 
OSCC_NLNM Group 
(n = 6)) 
OSCC_LNM Group 
(n = 12) 
Mean Age  61.4 (± 11.2) 68.2 (± 7.8) 67.4 (± 9.6) 
Gender      
 Male 3 (60%) 1 (16.7%) 8 (66.7%) 
 Female 2 (40%) 5 (83.3%) 4 (33.3%) 
Smoking Habit     
 Non-smokers 4 (80%) 4 (66.7%) 5 (41.7%) 
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 Non-drinkers 5 (100%) 5 (83.3%) 10 (83.3%) 
 Former drinkers 0 1 (16.7%) 2 (16.7%) 
Concerning OSCC sites, in the OSCC_NLNM group, the anterior 2/3 of the tongue 
was the most commonly affected site (n = 5, 83.3%), and the other OSCC affected the gum 
(n = 1, 16.7%). Regarding the OSCC_LNM group, the retromolar area was the most com-
monly affected site (n = 4; 33.3%), followed by the anterior 2/3 of tongue (n = 3; 25%), the 
gum (n = 2, 16.7%), the buccal mucosa (n = 2; 16.7%), and the floor of the mouth (n = 1; 
8.3%) (Table 2). 
Table 2. OSCC site in NLNM and LNM group. 
Group Age Sex OSCC Site Grading TNM Stage 
OSCC_NLNM 
F 69 Anterior 2/3 of tongue G2-G3 T1N0M0 I 
F 58 Anterior 2/3 of tongue G2-G3 T2N0M0 II 
F 70 Anterior 2/3 of tongue G3 T2N0M0 II 
F 67 Anterior 2/3 of tongue G3 T1N0M0 I 
F 83 Gum G2-G3 T2N0M0 II 
M 62 Anterior 2/3 of tongue G2 T2N0M0 II 
OSCC_LNM 
F 78 Gum G2 T2N1M0 III 
M 63 Retromolar area G2-G3 T4aN2bM0 IVA 
M 77 Buccal mucosa G2 T3N2M0 IVA 
F 74 Anterior 2/3 of tongue G2 T2N2aM0 IVA 
M 73 Retromolar area G2-G3 T3N1M0 III 
F 66 Gum G2-G3 T4aN2aM0 IVA 
M 48 Retromolar area G2 T3N2cM0 IVA 
F 82 Buccal mucosa G2-G3 T3N1M0 III 
M 54 Anterior 2/3 of tongue G3 T2N1M0 III 
M 67 Anterior floor of mouth G3 T4aN2M1 IVC 
M 66 Anterior 2/3 of tongue G3 T2N2cM0 IVA 
M 61 Retromolar area G3 T3N2bM1 IVC 
2.2. S/SEV Isolation and Protein Cargo Characterization 
As reported in the flowchart in Figure 1B, the small EVs were isolated from saliva by 
performing differential centrifugation and filtration of saliva samples collected from 5 
OSCC_FREE subjects and 18 patients with OSCC (6 NLNM and 12 LNM). The EV pellets 
belonging to the same group were then pooled and used for the analyses summarized in 
Figure 2. The protein cargo of the isolated SEVs was characterized by evaluating the pres-
ence of specific markers. In order to validate the protocol used for S/SEV isolation, we 
confirmed the presence of the EV markers HSC70 and CD63 in pooled S/SEV OSCC_FREE 
samples (Figure 3A). Moreover, the obtained reference protein library formed by 421 pro-
teins identified by ProteinPilot 4.5 at a 1% critical against the Homo sapiens UniProt fasta 
database (Supplementary Table S1—Protein Library and SWATH-MS Data, Sheet “Pro-
tein Library” and Table 3) was compared to the Vesiclepedia database by using FunRich 
software, in order to verify how many TOP10 and TOP100 EV proteins were present 
within our S/SEV OSCC protein dataset. The Venn diagram in Figure 3B showed that iso-
lated S/SEV contained all the TOP10 and more the 50% of the TOP100 EV proteins. Finally, 
the analysis performed by FunRich within the GO category “Cellular Component” 
(GO_CC) showed a good overlapping between the S/SEV protein dataset and the Vesi-
clepedia dataset referring to exosomes and nanovesicles (Figure 3C). Indeed, we found 
that the first six most represented terms are the same in the two analyzed datasets, even 
if there are differences in the percentage of proteins included in each group, probably due 
the major numeric complexity of the Vesiclepedia dataset. 




Figure 2. Workflow of the study. 
 
Figure 3. (A) Western blot revealing the presence of EV markers in representative in S/SEV OSCC_FREE pooled samples. 
(B) Venn diagram created using the stand-alone enrichment analysis tool FunRich (http://www.funrich.org) showing that 
among the proteins identified in S/SEV, there were all the TOP10 and more than 50% of the TOP100 EV proteins. (C) 
Percentage distribution of exosome/nanovesicle proteins reported in Vesiclepedia dataset (outer chart) and of the S/SEV 
proteins (inner chart) within the “Cellular Component” (CC) GO term. The top 6 represented CC_GO terms are reported. 
The analysis was performed using FunRich. 
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Number of identified proteins 
(DDA protein library) 
421 
Number of proteins quantified 
in SWATH-MS analysis 
365 
Number (and percentage) of quantified 
protein with CV ≤ 25% among technical 
replicates 
284 (78%) 284 (78%) 303 (83%) 
2.3. Protein Profile Characterization of S/SEVs. 
The obtained spectral reference library was then used for developing the SWATH-
MS strategy, and 7852 targeted peptides (filtered using an FDR threshold of ≤ 5% over 
nine runs) allowed obtaining of a detection rate of 75.3% (47314 of 62816), resulting in 
quantitative information for 365 proteins (Supplementary Table S1, sheet “SWATH-MS 
Data”). We found that among the technical replicates of each group, the percentage of 
proteins whose quantitation showed a coefficient of variation (CV) ≤ 25% in the quantita-
tive data was around 80% (Table 3 and Figure 4A). 
 
Figure 4. (A) Histogram shows the distribution of coefficients of variation (CV) among technical replicates of S/SEV 
OSCC_FREE, S/SEV OSCC_NLNM, and S/SEV OSCC_LNM. About 80% of the proteins have CV ≤ 25% (shadow area). (B) 
Volcano plot of the log2 fold change (x-axis) versus the -log10 BH corrected p-value (y-axis) of the 365 quantified proteins. 
The dashed lines correspond to 1.5-fold up and down (vertical lines), and a BY corrected p-value of 0.05 (horizontal line). 
In the plots, the yellow dots represent the proteins significantly up-represented and the blue ones the proteins significantly 
down-represented in the comparison indicated in the x-axis. (C) Heat map representing color-coded expression levels of 
proteins quantified in the three replicates of each group of pooled S/SEVs: yellow indicates high expression values and 
blue indicates low expression values. Details of regulated genes are provided in Supplementary Table S2. 
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In our analysis, we considered as differentially modulated proteins those showing a 
fold change (FC) > ± 1.5 (> 1.5 or < 0.067) in relative abundance and a corrected BY p-value 
≤ 0.05, indicated as yellow dots (up-represented) and blue (down-represented) in the vol-
cano plots in Figure 4B. In total, as summarized in Table 4, the significantly differentially 
modulated proteins were 235 in the comparison of S/SEV OSCC_FREE vs. S/SEV 
OSCC_NLNM (144 up-represented proteins and 91 down-represented), 157 in the com-
parison of S/SEV OSCC_FREE vs. S/SEV OSCC_LNM (68 up-represented proteins and 89 
down-represented), and 189 in the comparison of S/SEV OSCC_ NLNM vs. S/SEV 
OSCC_LNM (70 up-represented proteins and 119 down-represented). The high number 
of regulated proteins we found is due not only to the small sample size, but also to the 
small fold change cutoff that we set for getting a wide overview of differences character-
izing each of the analyzed S/SEV groups. This choice served the purpose of highlighting, 
rather than single proteins, an S/SEV protein profile to which was assigned the value of 
biomarker for OSCC. For these reasons, in this study we will not present analysis of single 
proteins, even if highly regulated, since this speculation should require a validation step 
on single S/SEV preparation. We have retained more useful and valid, according to the 
kind of used samples, to perform an analysis aimed at extrapolating a protein signature 
of OSCC S/SEVs. Further analyses will eventually be needed to propose specific proteins 
which can have a direct role in clinical practice, but this is not the aim of this study. 

















Number of modulated proteins  235 157 189 
Number of up-regulated proteins  144 68 70 
Number of down-regulated proteins  91 89 119 
Details of the performed quantitative analysis are reported in Supplementary Table 
S2, in sheets “SEV OSCC_FREE vs. SEV OSCC_NLNM”, “SEV OSCC_FREE vs. SEV 
OSCC_LNM”, and “SEV OSCC_ NLNM vs. SEV OSCC_LNM”, respectively. 
The modulation of the all-quantified protein, shown in the heat map in Figure 4C, 
highlighted that each S/SEV pool is specifically distinguished from the others by the group 
of proteins that are up-represented, corresponding to yellow bars framed by the dotted 
line. In light of this observation, among the significantly modulated proteins reported in 
the volcano plot in Figure 4C (and listed in the Supplementary Table S2), we extrapolated 
those that in each group (S/SEV OSCC_FREE, S/SEV OSCC_NLNM, and S/SEV 
OSCC_LNM) were significantly up-represented in comparison to the other two, showing 
a fold change (FC) ≥ 1.5 with BY p-value ≤ 0.05 (Tables 5–7). 
The analysis of these up-represented proteins performed using ClueGo allowed us 
to highlight three different clusters of enriched functional network terms (Adj p-value < 
0.05) for each of the three S/SEV subtypes (Figure 5A and Supplementary Table S3, sheet 
“ClueGO Results”), indicated as CLUSTER S/SEV OSCC_FREE, CLUSTER S/SEV 
OSCC_NLNM, and CLUSTER S/SEV OSCC_ LNM. Within the clusters, each node repre-
sents a term of “biological process” (circle) or a Reactome pathway (hexagon), and the 
arrows represent direct relations between the nodes. Nodes are specifically related to a 
cluster when at least 75% of the proteins of the node belong to that cluster (Table S3, sheet 
“ClueGO Results”). In Figure 5B, nodes/terms with the same color form a GO functional 
group, as specified in Figure 6 and in the Supplementary Table S3 (sheets “CLUSTER 
OSCC_FREE, “CLUSTER OSCC_NLNM”, and “CLUSTER OSCC_ LNM”). Interestingly, 
we found that these GO groups were unique for each cluster and defined a specific func-
tional signature of S/SEV OSCC_FREE, S/SEV OSCC_NLNM, and S/SEV OSCC_LNM 
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(Figure 6). Since it is known that the protein cargo of EVs often reflects that of the origi-
nating cells, the functional signature characterizing the three clusters can probably mirror 
the biological status and activities of the oral mucosa cells in the three analyzed clinical 
conditions. In particular, the ClueGo analysis highlighted five GO groups specifically as-
sociated with CLUSTER S/SEV OSCC_FREE, five with CLUSTER S/SEV OSCC_LNM, and 
seven with CLUSTER S/SEV OSCC_NLNM. Among the five GO groups identified in the 
CLUSTER S/SEV OSCC_FREE (Figure 6 and Supplementary Table S3), it was interesting 
to find the group “Detoxification of Reactive Oxygen Species“ (associated to ERO1A, 
GSTP1, PRDX1, PRDX6, TXN—see Table 5 for the FC in S/SEV OSCC_FREE), the group 
“Diseases associated with O-glycosilation of proteins” (associated to MUC 5, MUC7, and 
MUC16—see Table 5 for the FC in S/SEV OSCC_FREE), and the group “Keratinization” 
(associated to DSG3, KRT1, KRT10, KRT9, PRSS8, SPRR3—see Table 5 for the FC in S/SEV 
OSCC_FREE), all activities that can protect oral mucosa against cancer development [26–
31]. The last GO Group associated to the CLUSTER S/SEV OSCC_FREE was that of “Im-
mune-response-regulating cell surface receptor signaling pathway” (associated to several 
immunoglobulin heavy and light chains, RAP1A, CEACAM1, EZR, MUC16, MUC5B, 
MUC7, PIGR, PRDX1, RAP1A—see Table 5 for the FC in S/SEV OSCC_FREE), indicating 
that S/SEV OSCC_FREE are enriched in proteins involved in the modulation of immune 
response. 
 
Figure 5. (A) ClueGo analysis of the proteins up-represented in each of the three S/SEV subtypes highlighting different 
clusters of enriched functional network terms (Adj p-value < 0.05); (B) within each identified cluster, the terms/nodes with 
the same color form a GO functional groups (see for details Figure 6). Within the clusters, each node represents a term of 
“biological process” (circle) or a Reactome pathway (hexagon), and the arrows represent direct relations between the 
nodes. Nodes are specifically related to a cluster when at least the 75% of the proteins of the node belong to that cluster. 




Figure 6. Graphical representation of data obtained by ClueGo analysis. For each S/SEV OSCC cluster, the number of 
genes/term and the number of terms/functional GO are reported. 
Table 5. Proteins specifically up-represented in S/SEV OSCC_FREE. 
PROTEINS UP-REPRESENTED in S/SEV OSCC_FREE vs.  
S/SEV OSCC_NLNM and S/SEV OSCC_LNM 
 S/SEV OSCC_FREE vs.  
S/SEV OSCC_NLNM  
S/SEV OSCC_FREE vs.  
S/SEV OSCC_LNM 
Gene Name FC BY p-Value FC BY p-Value 
A2ML1 4.219 4.76 × 10−6 4.225 1.85 × 10−5 
ARHGDIB 20.046 5.94 × 10−5 2.205 7.94 × 10−4 
B4GALT1 2.344 5.92 × 10−5 2.381 2.26 × 10−5 
BPIFB2 4.057 2.66 × 10−4 1.774 1.29 × 10−2 
CD59 2.406 7.49 × 10−6 1.713 1.32 × 10−3 
CEACAM1 1.539 1.01 × 10−2 2.306 3.65 × 10−3 
CSTB 3.717 1.79 × 10−4 1.599 2.85 × 10−3 
DPP4 4.911 4.00 × 10−4 2.517 1.85 × 10−4 
DSG3 3.780 1.40 × 10−3 1.576 5.78 × 10−3 
ERO1A 3.741 1.02 × 10−4 4.327 7.30 × 10−4 
EZR 4.487 1.66 × 10−2 2.570 1.21 × 10−2 
FABP5 2.839 7.34 × 10−4 2.038 1.39 × 10−3 
FCGBP 3.124 3.82 × 10−6 1.782 7.47 × 10−5 
GDI2 4.233 7.87 × 10−5 2.101 2.39 × 10−2 
GLRX 3.345 8.31 × 10−4 1.514 1.55 × 10−2 
GSTP1 3.986 8.28 × 10−7 2.429 4.43 × 10−5 
IGHA1 1.682 3.01 × 10−4 1.600 1.35 × 10−2 
IGHA2 3.181 4.30 × 10−5 1.630 9.69 × 10−4 
IGHV1-2 3.206 1.63 × 10−4 1.645 2.01 × 10−3 
IGHV1-8 3.395 1.81 × 10−4 1.700 2.16 × 10−3 
IGHV3-15 2.833 2.06 × 10−5 3.462 4.43 × 10−5 
IGHV3-23 3.340 1.67 × 10−6 3.433 1.06 × 10−5 
IGHV3-7 2.175 8.91 × 10−5 2.790 9.93 × 10−5 
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IGHV3-72 2.703 2.01 × 10−2 3.301 2.48 × 10−2 
IGHV3-9 2.832 3.01 × 10−4 2.500 2.67 × 10−4 
IGHV4-31 3.132 1.40 × 10−4 2.467 1.67 × 10−4 
IGHV5-51 3.084 1.49 × 10−3 2.591 4.67 × 10−3 
IGKC 1.645 1.03 × 10−2 1.596 1.77 × 10−2 
IGKV1-13 16.563 3.57 × 10−4 7.833 8.21 × 10−4 
IGKV2-24 2.669 8.37 × 10−5 2.641 2.99 × 10−4 
IGKV2D-28 3.104 3.95 × 10−4 2.124 2.03 × 10−3 
IGKV3-7 1.867 3.35 × 10−4 1.808 4.58 × 10−4 
IGKV4-1 2.346 5.56 × 10−6 1.919 3.84 × 10−5 
IGLV1-47 2.801 2.63 × 10−5 1.718 1.28 × 10−2 
IL36A 2.991 3.74 × 10−4 2.180 3.70 × 10−4 
KLK1 2.371 3.57 × 10−4 1.789 1.84 × 10−3 
KLK11 2.869 7.32 × 10−3 1.883 2.90 × 10−2 
KRT1 6.860 4.30 × 10−5 3.514 6.68 × 10−4 
KRT10 3.864 2.32 × 10−5 3.157 3.29 × 10−4 
KRT9 9.278 5.09 × 10−5 5.088 8.53 × 10−5 
LEG1 7.471 1.78 × 10−5 2.021 4.70 × 10−4 
MIF 2.618 1.41 × 10−5 1.737 3.83 × 10−5 
MUC16 2.237 1.64 × 10−3 3.081 1.51 × 10−3 
MUC5B 2.996 1.29 × 10−4 1.652 1.21 × 10−3 
MUC7 4.333 9.18 × 10−5 1.968 9.74 × 10−4 
PAM 2.954 4.11 × 10−3 1.650 4.89 × 10−2 
PDCD6IP 3.097 6.34 × 10−4 2.913 1.80 × 10−3 
PFN1 4.645 4.67 × 10−5 1.539 4.63 × 10−3 
PIGR 3.157 5.56 × 10−6 1.712 7.35 × 10−5 
PRDX1 2.745 1.50 × 10−5 1.682 1.12 × 10−4 
PRDX6 2.902 1.52 × 10−3 1.995 5.45 × 10−3 
PROM1 3.190 7.64 × 10−4 1.613 8.08 × 10−3 
RAP1A 2.686 4.76 × 10−4 1.848 2.03 × 10−3 
SERPINB13 4.951 9.62 × 10−3 4.588 1.82 × 10−3 
SERPINB3 3.054 8.31 × 10−4 1.618 8.09 × 10−3 
SERPINB5 3.617 2.09 × 10−5 2.574 1.36 × 10−4 
SPRR3 5.290 1.49 × 10−3 2.303 8.08 × 10−3 
TFF3 3.929 5.57 × 10−3 2.641 1.49 × 10−2 
TXN 4.129 1.76 × 10−3 2.003 9.17 × 10−3 
YWHAZ 3.510 1.75 × 10−5 1.592 1.28 × 10−4 
ZG16B 11.069 2.42 × 10−6 1.548 2.01 × 10−4 
Within the CLUSTER S/SEV OSCC NLNM (Figure 6 and Supplementary Table S3), 
we found several GO groups reflecting well-known conditions associated with OSCC. In-
deed, our analysis highlighted that this cluster was characterized by the presence of pro-
teins involved in “acute inflammatory response” (the proteins associated to this GO group 
were several components of the complement system, some immunoglobulin heavy 
chains, A2M, AMBP, APCSCFH, CLU, F2, FGA, FGB, FGG, HPX, KLKB1, KNG1, ORM1, 
PROS1, SERPINs, and VTN—see Table 6 for the FC in S/SEV OSCC_NLNM), a condition 
characterizing the microenvironment and often modulated by the complement system 
[32,33]. Of note, the CLUSTER S/SEV OSCC_NLNM was also specifically associated with 
the GO groups of “regulation of blood coagulation” and “platelet degranulation” (associ-
ated to A1BG, A2M, AHSG, ALB, APCS, some apolipoproteins, CLU, ECM1, F2, FGA, 
FGB, FGG, FN1, HRG, ITIH4, KLKB1, KNG1, ORM1, PLG, PROS1, several SERPINs, TF, 
VTN—see Table 6 for the FC in S/SEV OSCC_NLNM). Finally, within the CLUSTER S/SEV 
OSCC_NLNM we found the GO group “plasma lipoprotein particle remodeling” (associ-
ated to A2M, ALB, APOA1, APOA2, APOB, APOC1, APOC3, APOE, ALB, APOA4—see 
Table 6 for the FC in S/SEV OSCC_NLNM). 
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Table 6. Proteins specifically up-represented in S/SEV OSCC_NLNM. 
PROTEINS UP-REPRESENTED in S/SEV OSCC_NLNM vs.  
S/SEV OSCC_FREE and S/SEV OSCC_LNM 
   S/SEV OSCC_NLNM vs. S/SEV OSCC_FREE   
S/SEV OSCC_NLNM vs. S/SEV 
OSCC_LNM 
Gene Name FC BY p-Value FC BY p-Value 
A1BG 2.798 2.10 × 10−2 1.592 2.75 × 10−4 
A2M 6.270 1.74 × 10−5 2.210 6.61 × 10−4 
AHSG 6.747 4.30 × 10−4 1.876 3.21 × 10−3 
ALB 4.256 1.36 × 10−7 2.626 2.88 × 10−6 
AMBP 14.291 4.88 × 10−4 2.456 5.62 × 10−3 
APCS 16.885 4.30 × 10−5 5.393 1.17 × 10−4 
APOA1 8.000 5.56 × 10−6 1.668 1.28 × 10−4 
APOA2 7.601 2.06 × 10−5 1.646 7.63 × 10−4 
APOA4 12.525 6.10 × 10−3 3.344 3.29 × 10−2 
APOB 4.968 1.66 × 10−5 4.149 9.25 × 10−5 
APOC1 33.965 1.13 × 10−5 4.655 5.97 × 10−5 
APOC3 5.447 2.16 × 10−2 5.776 6.82 × 10−4 
APOE 5.997 2.06 × 10−4 2.907 6.02 × 10−4 
APOH 5.406 8.31 × 10−4 7.510 7.17 × 10−4 
C1R 8.320 3.84 × 10−3 9.948 2.81 × 10−3 
C1S 21.978 5.91 × 10−5 6.646 4.85 × 10−4 
C3 8.758 1.43 × 10−5 2.998 9.25 × 10−5 
C4A 7.062 1.10 × 10−2 13.261 4.62 × 10−3 
C4B 13.800 1.63 × 10−4 14.008 4.44 × 10−4 
C4BPA 47.980 5.59 × 10−06 13.112 2.01 × 10−5 
C4BPB 22.217 6.19 × 10−5 6.869 1.60 × 10−3 
C5 8.230 3.04 × 10−3 1.962 3.29 × 10−2 
C6 35.474 7.87 × 10−5 3.882 3.77 × 10−2 
C7 7.835 2.23 × 10−4 2.299 5.19 × 10−3 
C8A 20.753 2.79 × 10−4 2.112 3.70 × 10−3 
C9 7.681 2.04 × 10−3 2.666 3.39 × 10−4 
CD5L 6.049 4.71 × 10−4 1.975 1.52 × 10−3 
CFB 4.768 8.31 × 10−4 6.263 1.15 × 10−3 
CFH 4.943 4.27 × 10−3 3.210 4.59 × 10−4 
CLU 1.810 7.34 × 10−4 2.291 6.55 × 10−4 
ECM1 1.876 1.08 × 10−4 1.685 1.20 × 10−3 
F2 20.900 4.76 × 10−6 9.344 3.13 × 10−5 
FGA 50.711 9.10 × 10−6 14.394 2.08 × 10−5 
FGB 38.017 8.28 × 10−7 7.917 2.88 × 10−6 
FGG 29.326 5.65 × 10−6 10.431 2.08 × 10−5 
FN1 14.280 2.32 × 10−5 5.879 2.08 × 10−5 
GC 5.916 3.35 × 10−4 2.567 2.69 × 10−3 
GLUL 2.553 5.29 × 10−4 5.317 6.49 × 10−4 
HABP2 18.099 6.53 × 10−5 12.473 2.17 × 10−4 
HBA1 4.942 3.79 × 10−6 1.524 1.50 × 10−4 
HBB 4.413 5.07 × 10−7 1.850 2.08 × 10−5 
HBD 2.964 1.33 × 10−3 2.189 6.93 × 10−3 
HP 9.067 5.07 × 10−7 2.988 2.88 × 10−6 
HPR 5.949 4.76 × 10−4 1.875 2.92 × 10−3 
HPX 4.703 5.01 × 10−5 2.413 5.15 × 10−5 
HRG 17.313 5.56 × 10−6 6.654 9.27 × 10−4 
IGHG1 5.954 1.47 × 10−6 1.899 2.08 × 10−5 
IGHG2 9.230 8.15 × 10−5 3.302 3.05 × 10−4 
IGHG3 15.347 2.31 × 10−4 7.226 5.95 × 10−5 
ITIH1 6.718 2.00 × 10−5 2.244 6.62 × 10−4 
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ITIH2 18.967 3.54 × 10−5 5.154 9.25 × 10−5 
ITIH4 8.286 2.42 × 10−6 4.882 7.04 × 10−6 
KLK13 1.811 1.25 × 10−3 1.578 1.33 × 10−4 
KLKB1 26.394 5.30 × 10−4 9.351 3.13 × 10−3 
KNG1 6.160 1.43 × 10−5 5.107 6.15 × 10−3 
LPA 26.553 5.07 × 10−7 5.994 3.38 × 10−5 
ORM1 27.811 5.65 × 10−6 9.577 9.54 × 10−6 
PLG 26.842 4.76 × 10−6 10.061 3.91 × 10−5 
PROS1 11.100 7.87 × 10−5 1.581 1.22 × 10−3 
SERPINA3 15.356 2.09 × 10−5 2.224 1.33 × 10−3 
SERPINA4 4.895 2.10 × 10−2 8.646 4.44 × 10−4 
SERPINC1 12.622 2.00 × 10−5 8.810 3.38 × 10−5 
SERPIND1 3.400 1.14 × 10−3 2.006 3.67 × 10−3 
SERPINF2 25.834 1.14 × 10−3 10.267 2.06 × 10−3 
TF 5.764 2.53 × 10−3 1.991 2.57 × 10−2 
VTN 40.677 5.07 × 10−7 6.165 4.22 × 10−5 
Among the five GO groups specifically characterizing the CLUSTER S/SEV 
OSCC_LNM, three were related to activities against pathogens (Figure 6 and Supplemen-
tary Table S3): “metal sequestration by antimicrobial proteins” (associated with LCN2, 
LTF, S100A9—see Table 7 for the FC in S/SEV OSCC_LNM); “growth of symbiont in host” 
(associated with ELANE, MPO, PGLYRP1—see Table 6 for the FC in S/SEV OSCC_LNM); 
and “antimicrobial peptides” (associated with ELANE, GAPDH, LCN2, LTF, MPO, 
PGLYRP1, PI3, PRTN3, RNASE3, S100A12, S100A9—see Table 7 for the FC in S/SEV 
OSCC_LNM). 
Table 7. Proteins specifically up-represented in S/SEV OSCC_LNM. 
PROTEINS UP-REPRESENTED in S/SEV OSCC_NLNM vs.  
S/SEV OSCC_FREE and S/SEV OSCC_LNM 
   S/SEV OSCC_NLNM vs.  S/SEV OSCC_FREE   
S/SEV OSCC_NLNM vs.  
S/SEV OSCC_LNM 
Gene Name FC BY p-Value FC BY p-Value 
ACTN1 1.641 3.62 × 10−3 2.970 1.25 × 10−3 
ACTR3 1.570 6.66 × 10−4 3.768 4.85 × 10−4 
ANXA3 1.951 8.08 × 10−3 2.258 4.60 × 10−3 
AZU1 13.474 2.60 × 10−3 2.253 1.34 × 10−2 
CA6 1.869 4.86 × 10−3 3.846 6.77 × 10−4 
CST5 1.509 6.38 × 10−3 2.083 1.01 × 10−3 
ELANE 14.603 7.16 × 10−5 2.648 1.25 × 10−4 
FCN1 2.756 1.09 × 10−4 4.392 4.63 × 10−4 
FTL 3.868 6.66 × 10−4 3.202 4.39 × 10−2 
GAPDH 2.107 1.33 × 10−2 2.718 6.49 × 10−3 
H2BC21 9.628 2.30 × 10−3 2.076 4.03 × 10−3 
KLK10 1.695 2.27 × 10−2 1.944 5.40 × 10−3 
KLK14 2.870 3.90 × 10−4 6.661 4.03 × 10−3 
LCN2 1.614 1.09 × 10−4 2.041 9.99 × 10−4 
LTA4H 1.553 1.66 × 10−2 5.109 1.42 × 10−2 
LTF 9.363 1.39 × 10−5 1.659 5.97 × 10−5 
MMP9 1.698 2.74 × 10−2 2.376 3.90 × 10−2 
MPO 10.720 1.08 × 10−6 2.478 2.88 × 10−6 
MYL6 2.264 4.11 × 10−3 1.654 2.91 × 10−3 
NUCB2 3.670 2.25 × 10−3 19.150 7.94 × 10−4 
PGLYRP1 1.659 3.29 × 10−4 2.814 9.25 × 10−5 
PI3 19.846 8.17 × 10−5 2.694 3.12 × 10−3 
PRB1 89.610 1.74 × 10−3 18.859 3.00 × 10−3 
PRR27 4.359 1.67 × 10−4 5.401 1.50 × 10−4 
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PRTN3 2.127 2.78 × 10−4 4.468 2.08 × 10−5 
PSMA5 3.158 1.67 × 10−2 3.295 2.32 × 10−2 
PSMB2 5.007 4.67 × 10−2 1.730 3.89 × 10−2 
RETN 2.731 7.47 × 10−5 1.676 9.25 × 10−5 
RNASE3 16.775 7.30 × 10−4 4.570 4.44 × 10−4 
S100A12 37.287 1.44 × 10−4 4.506 1.74 × 10−3 
S100A9 3.173 4.43 × 10−5 4.128 2.74 × 10−5 
SCGB3A1 2.108 1.03 × 10−4 3.282 6.47 × 10−5 
SMR3B 3.503 6.35 × 10−3 15.324 2.49 × 10−3 
TIMP1 2.154 7.47 × 10−5 5.408 3.40 × 10−6 
TKT 2.904 1.46 × 10−2 7.511 5.17 × 10−3 
TMEM198 80.329 9.30 × 10−5 33.058 9.25 × 10−5 
VCP 2.052 8.87 × 10−3 1.922 8.65 × 10−3 
3. Discussion 
An early and accurate diagnosis of OSCC often provides the best chance of survival 
and favorable outcomes as compared to diagnoses in advanced stages. To date, the visual 
inspection of the oral cavity followed by an incisional biopsy is still considered the gold 
standard diagnostic method for OSCC [2]. However, these approaches require the pres-
ence of lesions and visible alterations of oral mucosa, often not allowing the early capture 
of the latent or still asymptomatic malignant lesions. Thus, the availability of molecular 
biomarkers in the biological fluid becomes indispensable. In this context, blood and saliva 
EVs (B/EVs and S/EVs respectively) represent a valid source for detection of OSCC bi-
omarkers [34–36]. However, even though, due to the emerging exosome technologies, in-
teresting data on the diagnostic and prognostic values of miRNA and protein profiles of 
EVs has been available [37], many efforts for a deep molecular characterization of EVs are 
still needed, and further studies have to be performed to allow clinical applications of this 
knowledge. 
In this study, in order to provide new insights leading to the development of valid 
diagnostic and prognostic tools for OSCC, we performed a proteome quantitative 
SWATH-MS analysis of S/EVs isolated from healthy subjects and patients with NLNM 
and LNM OSCC. 
Unlike the shot-gun proteomic methods used to investigate S/EV proteomes [34], the 
targeted SWATH-MS strategy employed in this study is a specific variant of data-inde-
pendent acquisition (DIA) methods emerging as a technology that combines deep prote-
ome coverage capabilities with quantitative consistency and accuracy, making it a valid 
strategy for biomarker discovery [38,39]. 
Results showed that the S/SEV OSCC_FREE, S/SEV OSCC_NLNM, and S/SEV 
OSCC_LNM were characterized by the enrichment of specific proteins belonging to GO 
groups which defined a unique functional signature of each S/SEV cluster. Since it is 
known that the protein cargo of EVs often reflects that of the originating cells, the func-
tional signature characterizing the three clusters can probably mirror the biological status 
and activities of oral mucosa cells in the three analyzed clinical conditions. As reported in 
the “Results” section, among the GO groups identified in the CLUSTER S/SEV 
OSCC_FREE (Figure 6 and Supplementary Table S3), we found the group “detoxification 
of Reactive Oxygen Species“ (associated to ERO1A, GSTP1, PRDX1, PRDX6, TXN—see 
Table 5 for the FC in S/SEV OSCC_FREE), the group “diseases associated with O-glycosi-
lation of proteins” (associated to MUC 5, MUC7, and MUC16—see Table 5 for the FC in 
S/SEV OSCC_FREE), and the group “keratinization” (associated to DSG3, KRT1, KRT10, 
KRT9, PRSS8, SPRR3—see Table 5 for the FC in S/SEV OSCC_FREE), all activities that can 
protect oral mucosa against cancer development. Indeed, since it is well known that oxi-
dative stress and consequent ROS production are involved in the pathogenesis of oral 
cancer [30], the higher presence in S/SEV_FREE of proteins eliciting an anti-oxidative re-
sponse can mirror the condition of the originating cells, therefore indicating their ability 
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to protect oral mucosa from the pro-tumoral solicitations. Similarly, the higher presence 
in S/SEV_FREE of MUC 5, MUC7, and MUC16 may indicate a condition in which the oral 
mucosa of OSCC_FREE subjects is more protected from bacterial infections that are 
strictly related to oral carcinogenesis [29]. The mucins are highly O-glycosylated proteins 
forming the mucus gel layers on several organs with a tissue specificity, thus maintaining 
a continuous defensive barrier protection against all aggressive external forces [26]. In the 
oral cavity, the mucosal pellicle is mostly composed by the salivary mucins MUC5B, 
MUC7 (having antifungal, antibacterial, and antiviral functions), and by the secretory IgA 
(SIgA), which constitutes the main specific immune defense mechanism playing an im-
portant role in the homeostasis of the oral microbiota [28]. Due to this composition, the 
mucosal pellicle works as a protective layer, ensuring lubrication of the oral epithelia and 
also protection against excessive bacterial colonization [29]. Moreover, it is also known 
that beside their proper defensive action, mucins mediate the SIgA binding to the mucosal 
surface, thus influencing the immune activity of the mucosal pellicle [27]. The higher pres-
ence of mucins in S/SEV_FREE can indicate a better predisposition to prevent oral dysbio-
sis that emerging evidence suggests to be involved in oral cancer development [29]. In 
addition, the presence in the CLUSTER S/SEV OSCC_FREE of the GO group “keratiniza-
tion” may prompt a condition of well-being of the oral mucosa of OSCC_FREE subjects. 
Indeed, it is known that in the oral cavity, the keratinocytes, through a network of desmo-
somes and keratins, form a strong anatomical barrier that protects from both mechanical 
and chemical stress, as well as from microbial infections [31]. It was interesting to find 
within this GO group, the Small Proline Rich Protein 3 (SPRR3) recently proposed as a 
novel diagnostic and prognostic tumor marker of OSCC, since the survival analysis 
showed that its under-expression was associated to a poor prognosis, and that the de-
crease of SPRR3 expression corresponded to the increased the tumor malignancy [40]. 
Within CLUSTER S/SEV OSCC_NLNM, it was interesting to specifically find the GO 
groups of “regulation of blood coagulation” and “platelet degranulation” (associated to 
A1BG, A2M, AHSG, ALB, APCS, some apolipoproteins, CLU, ECM1, F2, FGA, FGB, FGG, 
FN1, HRG, ITIH4, KLKB1, KNG1, ORM1, PLG, PROS1, several SERPINs, TF, VTN) and 
the GO group “plasma lipoprotein particle remodeling” (associated to A2M, ALB, 
APOA1, APOA2, APOB, APOC1, APOC3, APOE, ALB, APOA4). Hypercoagulability is a 
recurrent condition of several types of cancer, causing the venous thromboembolism 
(VTE) that is a common complication in patients with cancer [41]. Thus, it was stimulating 
to find that CLUSTER S/SEV OSCC_NLNM was characterized by the presence of proteins 
associated with the coagulation process, which distinguished this cluster not only from 
that of S/SEV OSCC_FREE, but also from that of S/SEV OSCC_LNM. 
The role of lipid carriers in cancers is widely discussed, and emerging evidence high-
lights that the functionality and the impact of the apolipoproteins on the tumor microen-
vironment depend on the specific tissue context [42]. Interestingly, it was reported that 
stress-induced recruitment of lipoproteins and EVs represents a new mechanism of cancer 
cell adaptation, and that microenvironment changes induced by tumor cells can promote 
the formation of EV/lipoprotein complexes affecting the following entry and cargo trans-
fer into recipient cells [43]. 
Finally, the CLUSTER S/SEV OSCC_LNM was specifically associated to GO groups 
related to activities against pathogen agents, such as “metal sequestration by antimicro-
bial proteins” (associated to LCN2, LTF, S100A9—see Table 6 for the FC in S/SEV 
OSCC_LNM); “growth of symbiont in host” (associated to ELANE, MPO, PGLYRP1—see 
Table 6 for the FC in S/SEV OSCC_LNM); and “antimicrobial peptides” (associated to 
ELANE, GAPDH, LCN2, LTF, MPO, PGLYRP1, PI3, PRTN3, RNASE3, S100A12, 
S100A9—see Table 6 for the FC in S/SEV OSCC_LNM). Proteins of these groups, such as 
lactoferrin (LFT,), lipocalin-2 (LCN2), S100A9 (forming with S100A8 the heterodimeric 
complex calprotectin), neutrophil elastase (ELANE), peptidoglycan recognition protein 1 
(PGLYRP1), and myeloperoxidase (MPO), are widely described for their antibacterial ac-
tivity or for their role as inflammatory markers [44–48]. The enrichment of these proteins 
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in the S/SEVs from patients with OSCC_LNM could be indicative of dysbiotic signatures 
occurring during tumor progression. Evidence accumulated in the last years indicates that 
alterations of the oral microbiome can have a role in inducing oral cancer progression [49–
52]. Interestingly, some of these proteins (as S100 proteins and LCN2) are described as 
diagnostic and prognostic markers for several types of tumors, even though their role in 
oral cancer is controversial [48,53,54]. 
Taken together, obtained data support the use of S/SEVs as a promising diagnostic 
marker source for OSCC. Our approach presented here also has limitations, particularly 
with regard to the small number of patients enrolled and the numerical non-homogeneity 
of the groups analyzed, so further analyses must be performed using larger data sets. Fur-
thermore, since this proteomic study was performed on S/SEV pools, the validity of the 
predictive value of their protein cargo in OSCC will also have to be evaluated on single 
samples. 
4. Materials and Methods 
4.1. Subject Enrolment and Saliva Collection 
All participants were recruited from the Unit of Oral Medicine at the “Paolo Giac-
cone” Policlinico University Hospital in Palermo (Italy). The study protocol, which con-
formed with ethical guidelines of the 1964 Declaration of Helsinki and later amendments 
or comparable ethical standards, was approved by Institutional Ethics Committee of 
“Paolo Giaccone” Policlinico University Hospital in Palermo (Approval date: 6 February 
2013; approval number 3/2013). All patients signed written informed consent before spec-
imens were collected for the analyses. In total, 18 patients diagnosed with OSCC and 5 
subjects OCSS_FREE that were not on any medication and practiced regular oral hygiene 
were enrolled. 
All OSCC patients underwent surgery, including wide tumor excision and neck 
lymph node dissection and foe. Among them, 6 did not have lymph node metastasis 
(NLNM) and 12 did (LNM). Finally, three different groups were defined for the following 
analyses (Figure 1A): the OSCC_FREE group (n = 5), OSCC_NLNM group (n = 6), and 
OSCC_LNM group (n = 12). All subjects were asked to refrain from eating, drinking, or 
oral hygiene for at least one hour prior to collection. The volunteers were asked to rinse 
their mouth with 10 mL water with 0.9% saline to remove food debris and then waited for 
at least 5 min before collection of about 15 mL of saliva in 50 mL Falcon tubes. Once col-
lected, the saliva samples were immediately kept on dry ice and transported from the 
hospital to the laboratory for processing. If not immediately processed, the samples were 
stored at −80 °C until further analyses. 
4.2. Saliva SEV Isolation 
Each saliva sample was diluted 1:1 with phosphate-buffered saline (PBS) prior to 
proceed to SEV isolation following the experimental workflow shown in Figure 1B. As 
reported, the saliva samples were centrifuged at 300 × g for 5 min at 30 °C to eliminate the 
cells. Then, the supernatant was centrifugated at 3000 × g for 15 min at 4 °C, and further 
at 10,000 × g for 30 min at 4 °C to eliminate cell debris, other contaminants, and M/LEVs 
as well. Finally, the supernatant was filtered through a 0.45 μm VWR® Vacuum Filtration 
System (VWR International, West Chester, PA, USA), before ultracentrifugation (Ti70 or 
Ti45 rotor, Beckman Coulter, Brea, CA, USA) at 100,000 × g for 70 min at 4 °C to pellet the 
SVEs, which were finally resuspended in 100 μL PBS. 
In order to improve the protein amount and also to minimize the individual-to-indi-
vidual differences, the SEV pellets isolated from saliva samples (S/SEVs) of the same 
group were pooled. Thus, subsequent analyzes were carried out on three types of pooled 
samples: a) S/SEV OSCC_FREE; b) S/SEV OSCC_NLNM; and c) S/SEV OSCC_LNM. 
4.3. Western Blot 
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An aliquot of S/SEV OSCC_FREE sample was treated with RIPA lysis buffer with 
protease inhibitor cocktail [55]. Subsequently, lysates were centrifuged at 12,000 g for 1 h 
in ice, the supernatant was collected, and the protein concentration was determined by 
Bradford assay (Pierce, Rockford, IL, USA). Proteins were then separated using 4–12% 
Novex Bis-Tris SDS-acrylamide gels (Invitrogen, Waltham, Massachusetts, USA) and im-
munoblotted with the following primary antibodies: CD63 and HSC70 (Santa Cruz Bio-
technology, Inc., Santa Cruz, CA, USA). The secondary antibodies were obtained from 
Santa Cruz Biotechnology (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Chem-
iluminescence was detected using Amersham ECL Western Blotting Detection Reagent 
(Global Life Sciences Solutions, UK Amersham place, Little Chalfont, Buckinghamshire). 
4.4. Proteomic Analyses: In-Solution Protein Digestion and SWATH-MS Analysis 
Pooled S/SEVs (100 μg) were subjected to in-solution digestion using 50% 2,2,2-tri-
fluoroethanol (TFE) in PBS, and obtained peptides were desalted by solid phase extraction 
using Thermo Scientific Pierce C18 Spin Columns (Thermo Fisher Scientific) [56]. 
Equal amounts of peptides from each of the three samples were mixed to prepare a 
pool of tryptic peptides, which was subjected to Data-Dependent Acquisition (DDA) anal-
ysis. The resulting list of proteins/peptides was used for construction of the SWATH-MS 
reference spectral library. 
The analysis was performed by a Triple TOF 5600 Plus System equipped with an 
Eksigent Ekspert nano LC 425 system (AB Sciex, Framingham, USA). 
Pooled tryptic peptides (4 ug) were loaded in a C18 reverse-phase trap column (Ac-
claim PepMap 100 C18 LC Trap Column Thermo Fisher Scientific) at a flow rate of 5 
μL/min, using 0.1% v/v formic acid (FA) in water from a loading pump. Peptides were 
then separated on the Acclaim™ PepMap™ RSLC (75 μm × 25 cm nanoViper C18 2 μm 
100Å, Thermo Fisher Scientific) equilibrated at 40 °C with 0.1% FA in water (solvent A) at 
a flow rate of 300 nL/min) using 0.1% FA in ACN (solvent B), in accord with the following 
gradient method: linear increase of solvent B from 10 to 40% for 60 min and from 40% to 
70% for 15 min, further increase to 95% within 1 min, and maintenance at 95% for 5 min 
to rinse the analytical column. Finally, decrease of solvent B from 95 to 10% within 1 min, 
and hold at 10% for remaining 18 min to re-equilibrate the column. 
The mass spectrometer operated in MS scan (400 m/z to 1250 m/z; accumulation time 
250 ms) in high resolution mode (> 30,000) and in MS/MS scan (230 m/z to 1500 m/Z; ac-
cumulation time 65 ms) in high sensitivity mode (resolution > 15,000) with rolling collision 
energy. A maximum of 50 precursors per cycle from each MS spectrum, with charge states 
from 2 to 5, were fragmented if exceeding a threshold of 100 counts per second (cps), with 
a dynamic exclusion window of 12 s. 
The DDA file was submitted to Protein Pilot™ 4.5 software (AB SCIEX, Toronto, Can-
ada); Uniprot was used as the human protein database (downloaded in May 2020, 149,644 
protein sequence entries). The database search was performed with the Paragon algorithm 
by using the following parameters: iodoacetamide cysteine alkylation, digestion by tryp-
sin, and ID focus on biological modifications. 
For SWATH-MS analysis, 2 μg of each sample was analyzed in triplicate to avoid 
random variation by the following SWATH-MS mode: at a cycle time of 2 s, 50 ms TOF/MS 
survey scan was performed between 400 and 1250Da with 34 × 25 Da precursor isolation 
window (swath). SWATH MS/MS acquisition was carried out using a 76 ms accumulation 
time between 230 and 1500 Da.  
4.5. Bioinformatic and Statistical Analysis 
To evaluate the global protein composition of the S/SEV, the reference protein library 
obtained by the DDA analysis was compared with the Vesiclepedia database by using the 
stand-alone enrichment analysis tool FunRich (Functional Enrichment analysis tool; 
http://www.funrich.org) [57]. 
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Data from SWATH-MS analysis were processed by Peak View v2.2 and Marker View 
1.2.1 (AB SCIEX; Framingham, USA). In Peak View, data were analyzed using the follow-
ing parameters: 10 peptides, 7 transitions per peptide, 90% peptide confidence threshold, 
5% false discovery rate threshold (FDR), exclude modified peptides, extracted ion chro-
matogram (XIC) extraction window of 5 min, 0.05 Da XIC width. The protein list with 
FDR lower than 5% generated by analyzing SWATH-MS data with PeakView 2.2 was ex-
ported to MarkerView for normalization of protein intensity (peak area) using the total 
area sums algorithm and t-test analysis [58]. Proteins were considered to be differentially 
expressed if the fold change (FC) among the compared groups was > ± 1.5 (> 1.5 or < 0.067) 
with corrected p-value ≤ 0.05. 
The analyses of coefficients of variation, mean calculation, and Student’s t-test were 
performed by using Microsoft Excel 2016. Mean of the replicates was used to perform the 
following comparisons: (a) S/SEV OSCC_FREE vs. S/SEV OSCC_NLNM; (b) S/SEV 
OSCC_FREE vs. S/SEV OSCC_LNM; (c) S/SEV OSCC_NLNM vs. S/SEV OSCC_LNM. 
GraphPad Prism 9.00 for Windows was used for (i) performing the p-value Benjamini–
Yekutieli correction (BY p-value); (ii) to make a volcano plot scaling in which the FC was 
transformed using the log2 function, so that the data is centered on zero, while the BY 
corrected p-value was −log10 transformed [57]. The expression-based heat map was ob-
tained by using the Heatmapper freely available web server (http://www.heatmapper.ca), 
applying the following criteria: (a) clustering method: average linkage; (b) distance meas-
urement method: Kendall’s tau. To identify the biological processes and functional path-
ways specifically correlated to the protein cargo of S/EV OSCC_FREE, S/EV OSCC_ 
NLNM, and S/EV OSCC_ LNM, the bioinformatic tool ClueGO v2.5.2 + CluePedia v1.5.2, 
a Cytoscape v3.8.0 plug-in was used. This analysis allowed us to visualize the non-redun-
dant gene ontology (GO) terms (within the term “biological processes”) and functional 
pathways (searched in Reactome pathway database) in organized networks reflecting the 
relations between the biological groups based on the similarity of their linked genes/pro-
teins [59]. In order to make a group comparison and highlight functional differences, the 
three protein groups of up-regulated proteins were uploaded in ClueGO as separate clus-
ters using the Cytoscape environment [60]. For the enrichment of biological terms and 
functional groups, we used the two-sided (enrichment/depletion) test based on the hyper-
geometric distribution. We set the statistical significance to 0.05 (p ≤ 0.05), and we used 
the Benjamini–Hochberg adjustment to correct the p-value for the terms/groups visual-
ized by ClueGO. We used fusion criteria to diminish the redundancy of the terms shared 
by similar associated proteins. The used parameters were: kappa score threshold set to 
0.4; GO tree interval: 3–8; GO Term Fusion. 
5. Conclusions 
In conclusion, our study provides new evidence highlighting a S/SEV-based protein 
functional signature specifically associated to the absence of OSCC as well as to the LNM 
or LMN status, thus having a potential application value as novel predictive biomarkers 
for OSCC. The increase of sample size and the development of a validation phase based 
on targeted DIA strategies (as selected reaction monitoring), immunoassays, and so on, 
will be necessary to validate the S/SEV protein signature and the clinical value proposed. 
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